Related Experiment Video
Updated: Jul 5, 2026
Sequential In vivo Imaging of Osteogenic Stem/Progenitor Cells During Fracture Repair
Published on: May 23, 2014
Stimulation of fracture mineralization by salt-inducible kinase inhibitors
Kaveh Momenzadeh1, Diana Yeritsyan1, Mohammadreza Abbasian1
1Musculoskeletal Translational Innovation Initiative, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Introduction:
Over 6.8 million fractures occur annually in the US, with 10% experiencing delayed- or non-union. Anabolic therapeutics like PTH analogs stimulate fracture repair, and small molecule salt inducible kinase (SIK) inhibitors mimic PTH action. This study tests whether the SIK inhibitor YKL-05-099 accelerates fracture callus osteogenesis.
Methods:
126 female mice underwent femoral shaft pinning and midshaft fracture, receiving daily injections of PBS, YKL-05-099, or PTH. Callus tissues were analyzed via RT-qPCR, histology, single-cell RNA-seq, and μCT imaging. Biomechanical testing evaluated tissue rigidity. A hydrogel-based delivery system for PTH and siRNAs targeting SIK2/SIK3 was developed and tested.
Results:
YKL-05-099 and PTH-treated mice showed higher mineralized callus volume fraction and improved structural rigidity. RNA-seq indicated YKL-05-099 increased osteoblast subsets and reduced chondrocyte precursors. Hydrogel-released siRNAs maintained target knockdown, accelerating callus mineralization.
Discussion:
YKL-05-099 enhances fracture repair, supporting selective SIK inhibitors' development for clinical use. Hydrogel-based siRNA delivery offers targeted localized treatment at fracture sites.
Insights
The SIK inhibitor YKL-05-099 significantly accelerates fracture healing by promoting bone formation and improving tissue rigidity. This study supports the development of SIK inhibitors and localized hydrogel siRNA delivery for enhanced fracture repair.
Area of Science:
- Biomedical Engineering
- Orthopedics
- Pharmacology
Background:
- Over 6.8 million fractures occur annually in the US, with 10% resulting in delayed or non-union.
- Parathyroid hormone (PTH) analogs are anabolic therapeutics that stimulate fracture repair.
- Small molecule salt inducible kinase (SIK) inhibitors mimic PTH action, offering a potential therapeutic strategy.
Purpose of the Study:
- To investigate whether the SIK inhibitor YKL-05-099 accelerates fracture callus osteogenesis.
- To evaluate the efficacy of YKL-05-099 in promoting fracture healing in a mouse model.
- To explore a novel hydrogel-based delivery system for targeted fracture treatment.
Main Methods:
- 126 female mice underwent femoral shaft fracture surgery.
- Mice received daily injections of PBS, YKL-05-099, or PTH.
- Callus tissues were analyzed using RT-qPCR, histology, single-cell RNA-seq, μCT imaging, and biomechanical testing.
Main Results:
- YKL-05-099 and PTH treatment led to increased mineralized callus volume fraction and improved structural rigidity.
- Single-cell RNA-seq revealed that YKL-05-099 increased osteoblast populations and reduced chondrocyte precursors.
- Hydrogel-delivered siRNAs targeting SIK2/SIK3 effectively knocked down gene expression and accelerated callus mineralization.
Conclusions:
- YKL-05-099 demonstrates significant potential in enhancing fracture repair.
- Selective SIK inhibitors represent a promising class of drugs for clinical application in fracture healing.
- Hydrogel-based siRNA delivery provides a targeted, localized therapeutic approach for fracture sites.
More Related Videos
08:53Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
14:55Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis
Published on: June 24, 2018
